INCREASED PROOXIDANT ACTION OF HEPATIC CYTOSOLIC LOW-MOLECULAR-WEIGHT IRON IN EXPERIMENTAL IRON OVERLOAD

被引:41
作者
BRITTON, RS
FERRALI, M
MAGIERA, CJ
RECKNAGEL, RO
BACON, BR
机构
[1] LOUISIANA STATE UNIV,SCH MED,DEPT MED,GASTROENTEROL & HEPATOL SECT,SHREVEPORT,LA 71130
[2] CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106
关键词
D O I
10.1002/hep.1840110620
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In the iron‐loaded liver there may be an increase in the putative intracellular transit pool of iron, components of which could be catalytically active in stimulating lipid peroxidation. To study the levels of low‐molecular‐weight, catalytically active iron in the liver, cytosolic ultrafiltrates were tested in an assay containing rat liver microsomes and NADPH. Malondialdehyde production was used as an index of lipid peroxidation. This assay system was sensitive enough to detect 0.25 μmol/L ferrous iron; progressive but nonlinear increases in malondialdehyde were produced as the iron concentration was increased to 5 μmol/L. Ultrafiltrates from hepatic cytosol of iron‐loaded rats had greater prooxidant action than did those from controls. When added to the assay, deferoxamine, an iron chelator, completely suppressed the prooxidant action of hepatic ultrafiltrates, showing that this activity is iron‐dependent. Deferoxamine administered intraperitoneally to control animals at a dose of 1 gm/kg completely inhibited the prooxidant effect of hepatic ultrafiltrates prepared from rats killed after 1, 2 and 3 hr. Partial inhibition was observed at 4 hr; by 6 hr the inhibitory effect of deferoxamine was completely lost. Administration of deferoxamine (1 gm/kg intraperitoneally, 1 hr before killing) completely inhibited the prooxidant action of hepatic ultrafiltrates in moderately iron‐loaded rats and control but had no protective effect in heavily iron‐loaded rats. These results support the concept that iron overload results in an increase in a hepatic cytosolic pool of low‐molecular‐weight iron that is catalytically active in stimulating lipid peroxidation. This pool can be chelated transiently in vivo by deferoxamine in moderate, but not heavy, iron overload.(HEPATOLOGY 1990;11:1038‐1043.). Copyright © 1990 American Association for the Study of Liver Diseases
引用
收藏
页码:1038 / 1043
页数:6
相关论文
共 44 条
  • [1] Gordeuk VR, Bacon BR, Brittenham GM, Iron overload: causes and consequences, Annu Rev Nutr, 7, pp. 485-508, (1987)
  • [2] Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G, Survival and causes of death in cirrhotic and noncirrhotic patients with primary hemochromatosis, N Engl J Med, 313, pp. 1256-1262, (1985)
  • [3] Bassett ML, Halliday JW, Powell LW, Genetic hemochromatosis, Semin Liver Dis, 4, pp. 217-227, (1984)
  • [4] Tavill AS, Bacon BR, Hemochromatosis: iron metabolism and the iron overload syndromes, Hepatology: a textbook of liver disease, pp. 1273-1299, (1990)
  • [5] Bassett ML, Halliday JW, Powell LW, Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis, HEPATOLOGY, 6, pp. 24-29, (1986)
  • [6] Isaacson C, Seftel H, Keeley KJ, Bothwell TH, Siderosis in the Bantu: the relationship between iron overload and cirrhosis, J Lab Clin Med, 58, pp. 845-853, (1961)
  • [7] Bothwell TH, Isaacson C, Siderosis in the Bantu: a comparison of the incidence in males and females, BMJ, 1, pp. 522-524, (1962)
  • [8] Barry M, Flynn DM, Letsky EA, Risdon RA, Long‐term chelation therapy in thalassemia major: effect on liver iron concentration, liver histology and clinical progress, Br Med J, 2, pp. 16-20, (1974)
  • [9] Risdon RA, Barry M, Flynn DM, Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassemia, J Pathol, 116, pp. 83-95, (1975)
  • [10] Britton RS, Bacon BR, Recknagel RO, Lipid peroxidation and associated hepatic organelle dysfunction in iron overload, Chem Phys Lipids, 45, pp. 207-239, (1987)